Daewoong Pexuclu Celebrates 1st Anniversary... Aiming to Be a 'Game Changer' with 100 Billion Won in Sales

'Pexuclu Week' Held Until the 2nd of Next Month
Recent Cumulative Sales Surpass 30 Billion Won
"Aiming to Grow into a 100 Billion Won Product by Year-End"

Daewoong Pharmaceutical announced on the 28th that it will hold 'Fexuclue Week' until July 2nd to celebrate the 1st anniversary of the launch of the new drug for gastroesophageal reflux disease, 'Fexuclue.'

Daewoong Pharmaceutical Pexuclu 40mg.
[Photo by Daewoong Pharmaceutical]

'Fexuclue (active ingredient: fexuprazan hydrochloride)' is a new drug for gastroesophageal reflux disease developed independently by Daewoong Pharmaceutical, belonging to the potassium-competitive acid blocker (P-CAB) class. Fexuclue improves on the drawbacks of existing proton pump inhibitor (PPI) drugs, such as slow onset of action, dietary influence, and drug interactions. In particular, Fexuclue has the longest half-life of 9 hours among gastroesophageal reflux disease treatments. Marking its 1st anniversary on July 1st, Fexuclue recently surpassed cumulative sales of 30 billion KRW.

During Fexuclue Week, Daewoong Pharmaceutical will reexamine Fexuclue. From the 26th to the 29th, medical professionals from various specialties such as gastroenterology and cardiology will share the latest insights on prescribing Fexuclue through live seminars on the medical professional portal site 'Doctorville.'

On the first day of the live seminar, the 26th, Director Hyungjin Ahn (Gastroenterology, New Daesung Hospital) conducted a seminar titled ‘The Effect of Fexuclue Based on Case Studies.’ On the 27th, Dean Junghwa Jung (Cardiology, Chosun University Hospital) presented on ‘DAPT (Dual Antiplatelet Therapy) and GI bleeding: Strategies for Co-administration with Fexuclue.’ On the 28th, Professor Donggeun Lee (Otorhinolaryngology, Dong-A University Hospital) spoke on ‘The Role and Advantages of Fexuclue in LPRD (Laryngopharyngeal Reflux Disease) Treatment.’ On the final day, the 29th, Professor Yongchan Kim (Orthopedics, Kangdong Kyunghee University Hospital) discussed ‘Gastrointestinal Protection Strategies for Patients Taking NSAIDs (Nonsteroidal Anti-Inflammatory Drugs).’

Following this, on the 30th, an online 1st anniversary talk show will be held, chaired by Professor Seokchae Choi from the Gastroenterology Department at Wonkwang University Hospital. Gastroenterology experts will gather for a web talk show titled 'The Journey of Fexuclue,' discussing the achievements over the past year and future directions. Additionally, from July 1st to 2nd, the 'Fexuclue Symposium' will be held at the InterContinental Hotel COEX in Gangnam-gu, Seoul.

Since its launch, Fexuclue has shown growth in the domestic and international gastroesophageal reflux disease markets over the past year. According to UBIST, a pharmaceutical sample statistical information source, Fexuclue’s cumulative prescription amount exceeded 30 billion KRW in less than a year since its launch. It has also expanded into 18 countries overseas, including China and Brazil.

Changjae Lee, CEO of Daewoong Pharmaceutical, said, "It is a meaningful milestone to celebrate the 1st anniversary since successfully developing and launching Fexuclue. Going forward, we will further expand competitiveness based on Fexuclue’s solid strengths, aiming to grow it into a product worth around 100 billion KRW within this year and become a 'game changer' that shifts the treatment paradigm for gastroesophageal reflux disease from existing PPIs to P-CABs."

This content was produced with the assistance of AI translation services.